| FFT | fast Fourier transform; flicker fusion test or threshold |
|---|---|
| FIT | fluorescein isothiocyanate; fusion inferred threshold |
| FP | false positive; family physician; family planning; family practice; family practitioner; Fanconi pan... |
| MF | magnetic field; meat free; medium frequency; megafarad; membrane filler; merthiolate-formaldehyde [s... |
| SAPF | simultaneous anterior and posterior [spinal] fusion |
| HIV infections | Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru aids-related complex (arc), to acquired immunodeficiency syndrome (aids). (12 Dec 1998) |
|---|---|
| HIV integrase | <enzyme> Enzyme of the human immunodeficiency virus that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene. Registry number: EC 2.7.7.- (12 Dec 1998) |
| HIV long-terminal repeat | Regulatory sequences important for viral replication that are located on each end of the HIV genome. The ltr includes the HIV enhancer, promoter, and other sequences. Specific regions in the ltr include the negative regulatory element (nre), nf-kappa b binding sites , sp1 binding sites, tata box, and trans-acting responsive element (tar). The binding of both cellular and viral proteins to these regions regulates HIV transcription. (12 Dec 1998) |
| HIV protease | <enzyme> Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. Registry number: EC 3.4.23.- (12 Dec 1998) |
| HIV seronegativity | Immune status consisting of non-production of HIV antibodies, as determined by various serological tests. (12 Dec 1998) |
| HIV seropositivity | Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/lav). (12 Dec 1998) |
| HIV seroprevalence | Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV seropositivity). (12 Dec 1998) |
| HIV test | <investigation> A test which is performed on a standard venipuncture blood specimen which detects the presence of antibodies to HIV (virus). This test may not be positive for 3 to 6 months after infection with HIV. (27 Sep 1997) |
| HIV wasting syndrome | <syndrome> Involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhoea or fatigue for more than 30 days in the absence of a defined cause other than HIV infection. A constant feature is major muscle wasting with scattered myofibre degeneration. A variety of aetiologies, which vary among patients, contributes to this syndrome. (12 Dec 1998) |
| atrial fusion beat | A beat that occurs when the atria are activated in part by the sinus impulse and in part by an ectopic or retrograde impulse from A-V junction or ventricle. (05 Mar 2000) |
| magnetic confinement fusion | <physics> Method of fusion which uses magnetic fields / magnetic bottles to confine a hot plasma until fusion occurs. (09 Oct 1997) |
| gene fusion | Fusion of structural genes to analyze protein behaviour or fusion of regulatory sequences with structural genes to determine mechanisms of regulation. (12 Dec 1998) |
| ventricular fusion beat | A fusion beat that occurs when the ventricles are activated partly by the descending sinus or A-V junctional impulse and partly by an ectopic ventricular impulse. (05 Mar 2000) |
| recombinant fusion proteins | Proteins that are the result of genetic engineering. A regulatory part or promoter of one or more genes is combined with a structural gene. The fusion protein is formed after transcription and translation of the fused gene. This type of fusion protein is used in the study of gene regulation or structure-activity relationships. They might also be used clinically as targeted toxins (immunotoxins). (12 Dec 1998) |
| vertebral fusion | A procedure that involves fusing together two or more vertebrae in the spine using either bone grafts or metal rods (Harrington rods). This procedure may be used to correct kyphosis or scoliosis. It is also used in those who require spine stabilisation due to vertebral damage from ruptures discs, fractures, osteomyelitis, osteoarthritis or tumour. (27 Sep 1997) |